Available prognostic models for risk stratification of diffuse large b cell lymphoma patients: systemic review

Diffuse large B cell lymphoma (DLBCL) is the most common type of aggressive non-Hodgkin lymphomas (NHL). It is a clinically and biologically heterogeneous disease with a variable course. (Saygin et al., 2017). The most common used tool for prognostication in DLBCL patients still remains the International Prognostic Index (IPI), despite being created in the pre-rituximab era – (about 25 years ago) (Shipp et al., 1993). The prognostic significance of the IPI has been validated in several studies, including those which analysed rituximab-treated patients (Ziepert et al., 2010; Hosoda et al., 2018).
Source: Critical Reviews in Oncology Hematology - Category: Cancer & Oncology Authors: Source Type: research